Nordic Ignite invests in Simsen Diagnostics

We are delighted to announce our participation in Simsen Diagnostics' latest funding round, which raised 10 million SEK. Other investors in the round include Gobia Enterprises, JFB Invest, and GU Ventures.

Simsen Diagnostics will mainly use the capital to accelerate the sale of its proprietary product, Simsen Personal™, to biotech and pharmaceutical companies. Simsen Personal™ is an ultra-sensitive method for measuring the amount of circulating tumor DNA, enabling early detection of cancer recurrence and optimized treatment.

"We are excited about our investment in Simsen Diagnostics, a company with cutting-edge proprietary technology, poised for significant growth," said Rita Anson, co-founder of Nordic Ignite. "We have been impressed by the professionalism and vision of the core team and are proud to be partnering in this round with top-tier players in the life science sector to support Simsen Diagnostics' journey towards achieving its full potential."

Simsen Diagnostics develops technologies for ultra-sensitive analysis of complex DNA sources. Its solutions are both simple to use and specifically adapted for analysis of difficult-to-analyse DNA, such as circulating tumour DNA, a biomarker specific for cancer.